US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TRAWS PHARMA

1.49

-0.0100-0.67%

Pre-market: 1.570.0800+5.37%08:00 EDT

Volume:37.16K

Turnover:53.95K

Market Cap:7.62M

PE:-0.04

High:1.52

Open:1.47

Low:1.40

Close:1.50

Loading ...

Overview Company News Filings

BRIEF-Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma: Reports Positive Results From Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

THOMSON REUTERS

Traws Pharma: Conducting Similar Challenge Study in Non-Human Primates, With Data Expected in Q1 2025

THOMSON REUTERS

Traws Pharma: Topline Data From Ferret Model Testing Show That Tivoxavir Marboxil Has Potential to Inhibit Disease After Bird Flu Infection

THOMSON REUTERS

Traws Pharma Regains Compliance With Nasdaq Equity Listing Rule

THOMSON REUTERS

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

BRIEF-Traws Pharma Names Nora Brennan Interim CFO

Traws Pharma Inc - on February 5, Mark Guerin Resigned as CFO of Traws Pharma

THOMSON REUTERS

BRIEF-Traws Pharma Announces Completion Of Phase I Studies With Tivoxavir Marboxil

Traws Pharma Announces Completion of Phase I Studies With Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5n1 Bird Flu

THOMSON REUTERS

Traws Pharma Inc - No Significant Adverse Events Reported in Phase I Study

THOMSON REUTERS

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Traws Pharma files to sell 7.23M shares of common stock for holders

Traws Pharma, Expert Systems: Breakthrough in H5N1Bird Flu antiviral program

Expert Systems: Announced a Significant Milestone in a Development of Traws Pharma's H5n1 Antiviral Program

THOMSON REUTERS

Expert Systems: With Completion of Phase 1 Trials, Plans Are Underway to Initiate Phase 2 Efficacy Studies in First Half of 2025

THOMSON REUTERS

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Sector Update: Health Care Stocks Lower Monday Afternoon

MT Newswires Live

Crude Oil Gains 1%; Chicago PMI Falls In December

Traws Pharma to Raise Up to $72.6 Million Through Equity Offering; Shares Plunge Pre-Bell

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TRAW/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.49,"timestamp":1746561600000,"preClose":1.5,"halted":0,"volume":37159,"hourTrading":{"tag":"盘前","latestPrice":1.57,"preClose":1.49,"latestTime":"08:00 EDT","volume":10,"amount":15.700000000000001,"timestamp":1746619200744},"delay":0,"floatShares":4159569,"shares":5115900,"eps":-35.21255,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"05-07 08:35:14 EDT","open":1.47,"high":1.52,"low":1.4,"amount":53946.5889748,"amplitude":0.08,"askPrice":1.72,"askSize":20,"bidPrice":1.45,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-35.21255,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746624600000},"marketStatusCode":1,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.49,"preHourTrading":{"tag":"盘前","latestPrice":1.57,"preClose":1.49,"latestTime":"08:00 EDT","volume":10,"amount":15.700000000000001,"timestamp":1746619200744},"postHourTrading":{"tag":"盘后","latestPrice":1.5001,"preClose":1.49,"latestTime":"19:22 EDT","volume":243,"amount":366.0998,"timestamp":1746573753344},"volumeRatio":0.9744240574533451,"impliedVol":1.7917,"impliedVolPercentile":0.7872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","floatShares":4159569,"roa":"-65.35%","roe":"-2255.45%","lyrEps":-35.212551,"volumeRatio":0.9744240574533451,"shares":5115900,"dividePrice":0,"high":1.52,"amplitude":0.08,"preClose":1.5,"low":1.4,"week52Low":1.36,"pbRate":"-0.24","psRate":"33.73","week52High":19.44,"institutionHeld":0,"latestPrice":1.49,"committee":0.2,"eps":-35.21255,"divideRate":0,"volume":37159,"delay":0,"ttmEps":-35.21255,"open":1.47,"prevYearClose":8.88,"prevWeekClose":1.42,"prevMonthClose":1.45,"prevQuarterClose":2.3,"fiveDayClose":1.43,"twentyDayClose":1.9,"sixtyDayClose":7.95},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAW\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516684649","title":"BRIEF-Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684649","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684649?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:18","pubTimestamp":1741000710,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir MarboxilMarch 3  - Traws Pharma TRAW.O:TRAWS PHARMA: REPORTS POSITIVE RESULTS FROM ACCEPTED BIRD FLU MODEL FOR ANTI-VIRAL CANDIDATE, TIVOXAVIR MARBOXILTRAWS PHARMA: TOPLINE DATA FROM FERRET MODEL TESTING SHOW THAT TIVOXAVIR MARBOXIL HAS POTENTIAL TO INHIBIT DISEASE AFTER BIRD FLU INFECTIONTRAWS PHARMA: CONDUCTING SIMILAR CHALLENGE STUDY IN NON-HUMAN PRIMATES, WITH DATA EXPECTED IN Q1 2025Source text: [ID:]Further company coverage: TRAW.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2516681758","title":"Traws Pharma: Reports Positive Results From Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil","url":"https://stock-news.laohu8.com/highlight/detail?id=2516681758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516681758?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:06","pubTimestamp":1741000005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2516681713","title":"Traws Pharma: Conducting Similar Challenge Study in Non-Human Primates, With Data Expected in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516681713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516681713?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:06","pubTimestamp":1741000005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM024:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2516068173","title":"Traws Pharma: Topline Data From Ferret Model Testing Show That Tivoxavir Marboxil Has Potential to Inhibit Disease After Bird Flu Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2516068173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516068173?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:06","pubTimestamp":1741000005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM024:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2514532803","title":"Traws Pharma Regains Compliance With Nasdaq Equity Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2514532803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514532803?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nTUA5K9HDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2514913323","title":"Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2514913323","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514913323?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:00","pubTimestamp":1740744000,"startTime":"0","endTime":"0","summary":"NEWTOWN, Pa., Feb. 28, 2025  -- Traws Pharma, Inc.  , a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory viral diseases, announced today that it has received confirmation from Nasdaq that Traws has regained compliance with the minimum stockholders’ equity requirements of Nasdaq Listing Rule 5550, which requires listed companies to maintain a minimum of $2.5 million in stockholders’ equity. Accordingly, Traws common stock will continue to be listed and trade on The NASDAQ Capital Market under the symbol “TRAW”.Traws is committed to delivering novel compounds for unmet medical needs using state-of-t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-regains-compliance-nasdaq-120000952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","TSYW.SI","BK4588","BK4007","USJW.SI","BK4112","MNQmain","TQQQ","IE00B3QW5Z07.USD","QID","BK4215",".IXIC","NQmain","NDAQ","SQQQ","TRAW","BK4585","QLD","LU2095319765.USD","LU2210150020.SGD","EQR","IE00BKPKM429.USD","PSQ","LU2210149790.SGD","USAW.SI","NVIW.SI"],"gpt_icon":1},{"id":"2509774503","title":"BRIEF-Traws Pharma Names Nora Brennan Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2509774503","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509774503?lang=en_us&edition=fundamental","pubTime":"2025-02-08 05:43","pubTimestamp":1738964613,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Names Nora Brennan Interim CFOFeb 7  - Traws Pharma Inc TRAW.O:TRAWS PHARMA INC - ON FEBRUARY 5, MARK GUERIN RESIGNED AS CFO OF TRAWS PHARMATRAWS PHARMA INC - NORA BRENNAN APPOINTED INTERIM CFO OF TRAWS PHARMASource text: [ID:n0001104659-25-010580]Further company coverage: TRAW.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY12O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2509264771","title":"Traws Pharma Inc - on February 5, Mark Guerin Resigned as CFO of Traws Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264771","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509264771?lang=en_us&edition=fundamental","pubTime":"2025-02-08 05:32","pubTimestamp":1738963922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY12O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2505094905","title":"BRIEF-Traws Pharma Announces Completion Of Phase I Studies With Tivoxavir Marboxil","url":"https://stock-news.laohu8.com/highlight/detail?id=2505094905","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505094905?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:14","pubTimestamp":1737634466,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Announces Completion Of Phase I Studies With Tivoxavir MarboxilJan 23 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA ANNOUNCES COMPLETION OF PHASE I STUDIES WITH TIVOXAVIR MARBOXI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA33LX2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2505161091","title":"Traws Pharma Announces Completion of Phase I Studies With Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5n1 Bird Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2505161091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505161091?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA33LX2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2505091464","title":"Traws Pharma Inc - No Significant Adverse Events Reported in Phase I Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505091464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505091464?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA33LX2X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2505948630","title":"Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2505948630","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505948630?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633600,"startTime":"0","endTime":"0","summary":"Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention. NEWTOWN, Pa., Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced completion of Phase I clinical studies of its investigational one-dose influenza  therapy, tivoxavir marboxil , for the treatment or prevention of H5N1 bird flu.\"We believe that our clinical data in healthy volunteers support accelerated development of tivoxavir marboxil in response to the growing threat of bird flu,\" said Werner Cautreels, PhD, Chief Executive Officer of Traws Pharma.About Tivoxavir MarboxilSeasonal influenza represents an estimated multi-billion antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders1, with upside potential from pandemic flu ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/traws-pharma-announces-completion-phase-120000809.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/traws-pharma-announces-completion-phase-120000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4181","BK4218","LU1169589451.USD","LU1169590202.USD","TRAW","BK4023","CDC","CEN","BK4007","PD"],"gpt_icon":0},{"id":"2503614083","title":"Traws Pharma files to sell 7.23M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2503614083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503614083?lang=en_us&edition=fundamental","pubTime":"2025-01-15 19:40","pubTimestamp":1736941253,"startTime":"0","endTime":"0","summary":"06:35 EST Traws Pharma (TRAW) files to sell 7.23M shares of common stock for holders Published first on TheFly – the ultimate source for real-time,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-files-to-sell-7-23m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-files-to-sell-7-23m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2502494828","title":"Traws Pharma, Expert Systems: Breakthrough in H5N1Bird Flu antiviral program","url":"https://stock-news.laohu8.com/highlight/detail?id=2502494828","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502494828?lang=en_us&edition=fundamental","pubTime":"2025-01-11 07:00","pubTimestamp":1736550026,"startTime":"0","endTime":"0","summary":"Expert Systems announced a significant milestone in a development of Traws Pharma’s (TRAW) H5N1 antiviral program. The investigational drug, Tivoxa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-expert-systems-breakthrough-in-h5n1bird-flu-antiviral-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-expert-systems-breakthrough-in-h5n1bird-flu-antiviral-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2502846680","title":"Expert Systems: Announced a Significant Milestone in a Development of Traws Pharma's H5n1 Antiviral Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2502846680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502846680?lang=en_us&edition=fundamental","pubTime":"2025-01-11 06:58","pubTimestamp":1736549893,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O61CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2502638846","title":"Expert Systems: With Completion of Phase 1 Trials, Plans Are Underway to Initiate Phase 2 Efficacy Studies in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502638846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502638846?lang=en_us&edition=fundamental","pubTime":"2025-01-11 06:58","pubTimestamp":1736549893,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O61CZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2502846200","title":"Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2502846200","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502846200?lang=en_us&edition=fundamental","pubTime":"2025-01-11 06:55","pubTimestamp":1736549700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's  H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging results as a single-dose treatment for H5N1 avian influenza, representing a potentially pivotal advance in addressing this serious health challenge.Tivoxavir Marboxil, an oral cap-dependent endonuclease inhibitor, targets a highly conserved influenza protein, demonstrating broad-spectrum efficacy against various flu strains, including avian influenza. Preclinical studies have highlighted its potent activity against drug-resistant and highly pathogenic bird flu viruses, both in vitro and in vivo.\"The success of Tivoxavir Marboxil underscores the transformative potential of combining artificial intelligence with human expertise to tackle urgent global health challenges,\" said Tudor Oprea, Chief Executiv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/expert-systems-traws-pharma-report-225500223.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/expert-systems-traws-pharma-report-225500223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRAW","BK4007","CDC"],"gpt_icon":0},{"id":"2495257155","title":"Sector Update: Health Care Stocks Lower Monday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2495257155","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495257155?lang=en_us&edition=fundamental","pubTime":"2024-12-31 02:48","pubTimestamp":1735584523,"startTime":"0","endTime":"0","summary":"Health care stocks were declining Monday afternoon, with the NYSE Health Care Index down 0.9% and the Health Care Select Sector SPDR Fund  falling 1.1%.The iShares Biotechnology ETF  dropped 1.1%.In corporate news, Marinus Pharmaceuticals  shares surged 43% after the company said it signed a deal under which Immedica Pharma will buy all of its issued and outstanding stock for $0.55 a share.Emergent BioSolutions  shares jumped nearly 13% after HC Wainwright started coverage of the stock with a buy rating and $15 price target.Traws Pharma  shares tumbled over 39% after the company said it entered agreements to raise up to $72.6 million via an equity offering.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","XLV","BK4139","BK4583","BK4588","EBS","IBB","BK4007","BK4585","TRAW","MRNS"],"gpt_icon":0},{"id":"2495575292","title":"Crude Oil Gains 1%; Chicago PMI Falls In December","url":"https://stock-news.laohu8.com/highlight/detail?id=2495575292","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495575292?lang=en_us&edition=fundamental","pubTime":"2024-12-31 01:55","pubTimestamp":1735581325,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/12/42728374/crude-oil-gains-1-chicago-pmi-falls-in-december","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSAI","BK4583","BK4139","EBS","PSQ","QMCO","CVM","BK4170","USAW.SI","QID","BK4602","TQQQ","BK4539","TSYW.SI","TRAW","BK4124","CTKB","BK4007","NVIW.SI","SQQQ","MNQmain",".IXIC","QLD","NQmain","BK4121","USJW.SI"],"gpt_icon":1},{"id":"2495547008","title":"Traws Pharma to Raise Up to $72.6 Million Through Equity Offering; Shares Plunge Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2495547008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495547008?lang=en_us&edition=fundamental","pubTime":"2024-12-30 22:00","pubTimestamp":1735567218,"startTime":"0","endTime":"0","summary":"Traws Pharma  said Monday it entered agreements to raise up to $72.6 million through an equity offering.An initial tranche of $20 million will involve the sale of around 3.9 million shares of common stock and pre-paid warrants, with an additional $52.6 million contingent on the exercise of non-prepaid warrants tied to upcoming bird flu data milestones in early and mid-2025, Traws Pharma said.Closing is expected around Tuesday, the company said.Traws Pharma shares plunged more than 37% in recent premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","TRAW","BK4585","EQR","BK4215","BK4007"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":64,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"TRAW","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":95.66},{"market":"US","date":"2024-11-14","symbol":"TRAW","fiscalQuarterEnding":"2024/09","expectedEps":-6.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-8.81},{"market":"US","date":"2024-09-23","symbol":"TRAW","defaultRemindTime":1727098200000,"type":"split","dateTimestamp":1727064000000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2024-08-15","symbol":"TRAW","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723694400000,"reportTimeType":"pre","actualEps":-4.87},{"market":"US","date":"2024-05-15","symbol":"TRAW","fiscalQuarterEnding":"2024/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAW","date":"2025-05-06","current":-0.045704,"percent":0.980237,"low":-0.930105,"twenty":-0.670346,"median":-0.111536,"eighty":-0.066096,"high":-0.042961,"avg":-0.274867,"sd":0.28349,"marketCap":7610685},"quantilePoints":[{"date":"2024-04-05","current":-0.930105,"twenty":-0.930105,"median":-0.930105,"eighty":-0.930105,"marketCap":17623624},{"date":"2024-04-12","current":-0.875242,"twenty":-0.899279,"median":-0.879971,"eighty":-0.87246,"marketCap":16584087},{"date":"2024-04-19","current":-0.774197,"twenty":-0.884701,"median":-0.859217,"eighty":-0.774642,"marketCap":14669484},{"date":"2024-04-26","current":-0.703922,"twenty":-0.875242,"median":-0.784323,"eighty":-0.745597,"marketCap":13337908},{"date":"2024-05-03","current":-0.713993,"twenty":-0.87246,"median":-0.75973,"eighty":-0.713993,"marketCap":13528735},{"date":"2024-05-10","current":-0.722239,"twenty":-0.859217,"median":-0.743093,"eighty":-0.71377,"marketCap":13684982},{"date":"2024-05-17","current":-0.7463,"twenty":-0.799236,"median":-0.738475,"eighty":-0.713993,"marketCap":13549821},{"date":"2024-05-24","current":-0.73457,"twenty":-0.794005,"median":-0.741761,"eighty":-0.718444,"marketCap":13336853},{"date":"2024-05-31","current":-0.675921,"twenty":-0.778515,"median":-0.736522,"eighty":-0.713681,"marketCap":12272014},{"date":"2024-06-07","current":-0.836261,"twenty":-0.794624,"median":-0.73457,"eighty":-0.711322,"marketCap":15183160},{"date":"2024-06-14","current":-0.873049,"twenty":-0.83888,"median":-0.740589,"eighty":-0.71288,"marketCap":15851082},{"date":"2024-06-21","current":-0.649387,"twenty":-0.836845,"median":-0.738475,"eighty":-0.709541,"marketCap":11790270},{"date":"2024-06-28","current":-0.62709,"twenty":-0.83835,"median":-0.738475,"eighty":-0.706993,"marketCap":11385454},{"date":"2024-07-05","current":-0.557395,"twenty":-0.836651,"median":-0.734469,"eighty":-0.698614,"marketCap":10120072},{"date":"2024-07-12","current":-0.483661,"twenty":-0.814046,"median":-0.728873,"eighty":-0.672205,"marketCap":8781358},{"date":"2024-07-15","current":-0.554747,"twenty":-0.806641,"median":-0.726171,"eighty":-0.663181,"marketCap":10071990},{"date":"2024-08-02","current":-0.532446,"twenty":-0.799236,"median":-0.724978,"eighty":-0.649387,"marketCap":9667086},{"date":"2024-08-09","current":-0.491259,"twenty":-0.797102,"median":-0.722239,"eighty":-0.600613,"marketCap":8919304},{"date":"2024-08-16","current":-0.066488,"twenty":-0.794005,"median":-0.718444,"eighty":-0.532446,"marketCap":9112137},{"date":"2024-08-23","current":-0.065565,"twenty":-0.774642,"median":-0.71377,"eighty":-0.508851,"marketCap":8985580},{"date":"2024-08-30","current":-0.06743,"twenty":-0.774197,"median":-0.709986,"eighty":-0.494812,"marketCap":9241226},{"date":"2024-09-06","current":-0.06538,"twenty":-0.762623,"median":-0.702951,"eighty":-0.490604,"marketCap":8960268},{"date":"2024-09-13","current":-0.062794,"twenty":-0.758648,"median":-0.694503,"eighty":-0.071087,"marketCap":8605907},{"date":"2024-09-20","current":-0.057254,"twenty":-0.751084,"median":-0.683063,"eighty":-0.068232,"marketCap":7846562},{"date":"2024-09-27","current":-0.081301,"twenty":-0.74722,"median":-0.649387,"eighty":-0.067774,"marketCap":11142278},{"date":"2024-10-04","current":-0.073971,"twenty":-0.746382,"median":-0.624791,"eighty":-0.068232,"marketCap":10137646},{"date":"2024-10-11","current":-0.065174,"twenty":-0.745738,"median":-0.557395,"eighty":-0.067596,"marketCap":8932088},{"date":"2024-10-18","current":-0.062642,"twenty":-0.744673,"median":-0.543597,"eighty":-0.067316,"marketCap":8585034},{"date":"2024-10-25","current":-0.111702,"twenty":-0.743234,"median":-0.515682,"eighty":-0.066488,"marketCap":15308680},{"date":"2024-10-31","current":-0.109715,"twenty":-0.741526,"median":-0.508851,"eighty":-0.066652,"marketCap":15036392},{"date":"2024-11-08","current":-0.111592,"twenty":-0.739321,"median":-0.498158,"eighty":-0.06682,"marketCap":15293553},{"date":"2024-11-15","current":-0.123204,"twenty":-0.736132,"median":-0.492107,"eighty":-0.067201,"marketCap":16884930},{"date":"2024-11-22","current":-0.096923,"twenty":-0.734509,"median":-0.489621,"eighty":-0.06743,"marketCap":13645248},{"date":"2024-11-29","current":-0.098427,"twenty":-0.734469,"median":-0.48099,"eighty":-0.067496,"marketCap":13857037},{"date":"2024-12-06","current":-0.108407,"twenty":-0.733312,"median":-0.130241,"eighty":-0.067596,"marketCap":15262104},{"date":"2024-12-13","current":-0.104014,"twenty":-0.729414,"median":-0.121316,"eighty":-0.067685,"marketCap":14643681},{"date":"2024-12-20","current":-0.114642,"twenty":-0.725217,"median":-0.114642,"eighty":-0.068025,"marketCap":16139817},{"date":"2024-12-27","current":-0.244993,"twenty":-0.723719,"median":-0.117501,"eighty":-0.068353,"marketCap":34491315},{"date":"2025-01-03","current":-0.186323,"twenty":-0.723452,"median":-0.123204,"eighty":-0.068427,"marketCap":26231553},{"date":"2025-01-10","current":-0.173429,"twenty":-0.722482,"median":-0.130241,"eighty":-0.069344,"marketCap":24416220},{"date":"2025-01-17","current":-0.146996,"twenty":-0.721141,"median":-0.147157,"eighty":-0.069786,"marketCap":20694789},{"date":"2025-01-24","current":-0.13797,"twenty":-0.719413,"median":-0.140763,"eighty":-0.070056,"marketCap":19424056},{"date":"2025-01-31","current":-0.156666,"twenty":-0.718444,"median":-0.146996,"eighty":-0.070643,"marketCap":22056288},{"date":"2025-02-07","current":-0.178157,"twenty":-0.715773,"median":-0.153981,"eighty":-0.07105,"marketCap":25081842},{"date":"2025-02-14","current":-0.173739,"twenty":-0.713859,"median":-0.157526,"eighty":-0.072709,"marketCap":24459897},{"date":"2025-02-21","current":-0.121618,"twenty":-0.713592,"median":-0.156666,"eighty":-0.073848,"marketCap":17121928},{"date":"2025-02-28","current":-0.087129,"twenty":-0.71288,"median":-0.149414,"eighty":-0.074131,"marketCap":12266456},{"date":"2025-03-07","current":-0.070533,"twenty":-0.710432,"median":-0.144632,"eighty":-0.071013,"marketCap":9929988},{"date":"2025-03-14","current":-0.07157,"twenty":-0.706225,"median":-0.135069,"eighty":-0.071013,"marketCap":10076017},{"date":"2025-03-21","current":-0.074682,"twenty":-0.703145,"median":-0.130241,"eighty":-0.070984,"marketCap":10514105},{"date":"2025-03-28","current":-0.066643,"twenty":-0.70173,"median":-0.123448,"eighty":-0.070533,"marketCap":9382378},{"date":"2025-04-04","current":-0.066422,"twenty":-0.698614,"median":-0.121618,"eighty":-0.069679,"marketCap":11060862},{"date":"2025-04-11","current":-0.053321,"twenty":-0.692996,"median":-0.117957,"eighty":-0.068372,"marketCap":8879132},{"date":"2025-04-17","current":-0.060633,"twenty":-0.690629,"median":-0.115407,"eighty":-0.067596,"marketCap":10096842},{"date":"2025-04-25","current":-0.046618,"twenty":-0.687348,"median":-0.111751,"eighty":-0.066971,"marketCap":7762898},{"date":"2025-05-02","current":-0.042961,"twenty":-0.674063,"median":-0.111618,"eighty":-0.066488,"marketCap":7154043},{"date":"2025-05-06","current":-0.045704,"twenty":-0.670346,"median":-0.111536,"eighty":-0.066096,"marketCap":7610685}],"updateTime":1746621314645}}}